Medication safety - risk–benefit analysis for prescribing anticoagulants

Principles

Rational prescribing requires explicit risk-benefit analysis weighing expected therapeutic benefit against the specific risks for that individual patient (adverse effect profile, interaction risk, monitoring burden) and against the alternative of not prescribing - this analysis should be individualised rather than applying population-level evidence uniformly regardless of the specific patient's circumstances
A foundational principle underlying every prescribing decision, though its explicit, structured application is particularly emphasised in complex, high-risk, or finite-benefit scenarios (e.g. limited life expectancy, high interaction potential, narrow therapeutic index agents)

Population-level trial evidence establishes average risk-benefit balance, but individual patient factors (age, frailty, comorbidity, life expectancy, personal values and preferences) can shift this balance substantially for a specific patient - explaining why guideline-recommended treatment is not automatically appropriate for every individual patient meeting the guideline's inclusion criteria

Time-to-benefit consideration is particularly relevant in patients with limited life expectancy - a preventive medication with a benefit horizon (time before risk reduction becomes measurable) longer than the patient's expected remaining lifespan offers little realistic benefit while still carrying ongoing risk and burden
Patient values and preferences should be explicitly incorporated into the risk-benefit discussion, not treated as secondary to the clinician's assessment of objective risk-benefit alone

Explicit discussion of risk-benefit trade-offs with the patient supports genuinely informed, shared prescribing decisions, particularly for treatments with a finite or uncertain benefit given the individual patient's circumstances
Regular reassessment of the risk-benefit balance over time (not just at initial prescribing) as the patient's circumstances, life expectancy, or treatment tolerance change

Time-to-benefit mismatch with limited life expectancy (e.g. statin therapy in advanced frailty/terminal illness), individualising guideline-based recommendations to patient-specific circumstances, incorporating patient values into prescribing decisions

A medication's population-level trial benefit does not automatically translate to net benefit for every individual patient - when a preventive treatment's time-to-benefit exceeds a patient's realistic remaining life expectancy, continuing it provides little practical benefit while still carrying ongoing risk and pill burden, making deprescribing the more rational choice in this specific scenario

5 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.